These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation]. Matsushita T, Akatsuka Y, Towatari M, Takeyama K, Miyamura K, Sugihara T, Minami S, Kodera Y. Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437 [Abstract] [Full Text] [Related]
24. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756 [Abstract] [Full Text] [Related]
25. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J, Ringdén O. Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [Abstract] [Full Text] [Related]
26. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J. Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761 [Abstract] [Full Text] [Related]
28. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y. Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440 [Abstract] [Full Text] [Related]
29. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J, Fefer A, Anasetti C, Beatty P, Bensinger W. Bone Marrow Transplant; 1991 Jun; 7(6):453-9. PubMed ID: 1873592 [Abstract] [Full Text] [Related]
30. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, Dallorso S, Di Bartolomeo P, Fagioli F, Locasciulli A, Lawler M, Bacigalupo A. Blood; 2000 Sep 01; 96(5):1690-7. PubMed ID: 10961865 [Abstract] [Full Text] [Related]
33. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Beelen DW, Quabeck K, Kaiser B, Wiefelspütz J, Scheulen ME, Graeven U, Grosse-Wilde H, Sayer HG, Schaefer UW. Transplantation; 1990 Sep 01; 50(3):421-7. PubMed ID: 2402791 [Abstract] [Full Text] [Related]
34. Marrow transplant experience for children with severe aplastic anemia. Sanders JE, Storb R, Anasetti C, Deeg HJ, Doney K, Sullivan KM, Witherspoon RP, Hansen J. Am J Pediatr Hematol Oncol; 1994 Feb 01; 16(1):43-9. PubMed ID: 8311172 [Abstract] [Full Text] [Related]
38. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC. Bone Marrow Transplant; 1996 Nov 15; 18(5):921-9. PubMed ID: 8932846 [Abstract] [Full Text] [Related]